Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - meropenem trihydrate 1140 mg - eq. meropenem 1000,1 mg - powder for solution for injection/infusion - 1 g - meropenem trihydrate 1140 mg - meropenem

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - meropenem trihydrate 1140 mg - eq. meropenem 1000,1 mg - powder for solution for injection/infusion - meropenem

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - meropenem trihydrate 1140 mg - eq. meropenem 1000,1 mg - powder for solution for injection/infusion - meropenem

United States - English - NLM (National Library of Medicine)

hospira, inc. - meropenem (unii: fv9j3ju8b1) (meropenem anhydrous - unii:yop6px0bao) - meropenem 500 mg in 10 ml - meropenem for injection i.v. is indicated for the treatment of complicated skin and skin structure infections (csssi) due to staphylococcus aureus (methicillin-susceptible isolates only), streptococcus pyogenes, streptococcus agalactiae, viridans group streptococci, enterococcus faecalis (vancomycin-susceptible isolates only), pseudomonas aeruginosa, escherichia coli, proteus mirabilis, bacteroides fragilis, and peptostreptococcus species. meropenem for injection i.v. is indicated for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, escherichia coli , klebsiella pneumoniae , pseudomonas aeruginosa , bacteroides fragilis , b. thetaiotaomicron , and peptostreptococcus species. meropenem for injection i.v. is indicated for the treatment of bacterial meningitis caused by haemophilus influenzae , neisseria meningitidis, and penicillin-susceptible isolates of streptococcus pneumoniae. meropenem for injection i.v. has been found to be effective in eliminating co

United States - English - NLM (National Library of Medicine)

daewoong america inc. - meropenem (unii: fv9j3ju8b1) (meropenem anhydrous - unii:yop6px0bao) - meropenem 500 mg in 20 ml - meropenem for injection is indicated for the treatment of complicated skin and skin structure infections (csssi) due to staphylococcus aureus (methicillin-susceptible isolates only), streptococcus pyogenes, streptococcus agalactiae, viridans group streptococci, enterococcus faecalis (vancomycin-susceptible isolates only), pseudomonas aeruginosa, escherichia coli, proteus mirabilis, bacteroides fragilis, and peptostreptococcus species. meropenem for injection is indicated for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, bacteroides fragilis, b. thetaiotaomicron, and peptostreptococcus species. meropenem for injection is indicated for the treatment of bacterial meningitis caused by haemophilus influenzae, neisseria meningitidis and penicillin-susceptible isolates of stre

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - meropenem (unii: fv9j3ju8b1) (meropenem anhydrous - unii:yop6px0bao) - meropenem 500 mg in 10 ml - meropenem for injection, usp (i.v.) is indicated for the treatment of complicated skin and skin structure infections (csssi) due to staphylococcus aureus (methicillin-susceptible isolates only), streptococcus pyogenes, streptococcus agalactiae, viridans group streptococci, enterococcus faecalis (vancomycin-susceptible isolates only), pseudomonas aeruginosa, escherichia coli, proteus mirabilis, bacteroides fragilis, and peptostreptococcus species. meropenem for injection, usp (i.v.) is indicated for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, escherichia coli , klebsiella pneumoniae , pseudomonas aeruginosa , bacteroides fragilis , b. thetaiotaomicron , and peptostreptococcus species. meropenem for injection, usp (i.v.) is indicated for the treatment of bacterial meningitis caused by haemophilus influenzae , neisseria meningitidis and penicillin-susceptible isolates of streptococcus pneumoniae . meropenem for injection, usp (i.v.) has been found to be

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - meropenem trihydrate, quantity: 570.5 mg (equivalent: meropenem, qty 500 mg) - injection, powder for - excipient ingredients: sodium carbonate - meropenem is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: community acquired lower respiratory tract infection; hospital acquired lower respiratory tract infection; complicated urinary tract infection; febrile neutropenia; intra-abdominal and gynaecological (poly microbial) infections; complicated skin and skin structure infections; meningitis; septicaemia

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - meropenem trihydrate, quantity: 1141 mg (equivalent: meropenem, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - meropenem is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: community acquired lower respiratory tract infection; hospital acquired lower respiratory tract infection; complicated urinary tract infection; febrile neutropenia; intra-abdominal and gynaecological (poly microbial) infections; complicated skin and skin structure infections; meningitis; septicaemia

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - meropenem trihydrate, quantity: 570 mg (equivalent: meropenem, qty 500 mg) - injection, powder for - excipient ingredients: sodium carbonate - meropenem ranbaxy is indicated for the treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: - community acquired lower respiratory tract infection, - hospital acquired lower respiratory tract infection, - complicated urinary tract infection, - febrile neutropenia, - intra-abdominal and gynaecological (polymicrobial) infections, - complicated skin and skin structure infections, - meningitis, - septicaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - meropenem trihydrate, quantity: 1140 mg (equivalent: meropenem, qty 1 g) - injection, powder for - excipient ingredients: sodium carbonate - meropenem ranbaxy is indicated for the treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: - community acquired lower respiratory tract infection, - hospital acquired lower respiratory tract infection, - complicated urinary tract infection, - febrile neutropenia, - intra-abdominal and gynaecological (polymicrobial) infections,- complicated skin and skin structure infections, - meningitis, - septicaemia.